Vietnam · Delayed Price · Currency is VND Imexpharm Statistics
Total Valuation
Imexpharm has a market cap or net worth of VND 5.51 trillion. The enterprise value is 5.20 trillion.
| Market Cap | 5.51T |
| Enterprise Value | 5.20T |
Important Dates
The next estimated earnings date is Tuesday, January 19, 2027.
| Earnings Date | Jan 19, 2027 |
| Ex-Dividend Date | Jul 13, 2026 |
Share Statistics
Imexpharm has 154.01 million shares outstanding. The number of shares has increased by 0.93% in one year.
| Current Share Class | 154.01M |
| Shares Outstanding | 154.01M |
| Shares Change (YoY) | +0.93% |
| Shares Change (QoQ) | -17.98% |
| Owned by Insiders (%) | 0.88% |
| Owned by Institutions (%) | 0.78% |
| Float | 1.48M |
Valuation Ratios
The trailing PE ratio is 17.01 and the forward PE ratio is 15.54.
| PE Ratio | 17.01 |
| Forward PE | 15.54 |
| PS Ratio | 2.40 |
| PB Ratio | 2.27 |
| P/TBV Ratio | 2.34 |
| P/FCF Ratio | 15.73 |
| P/OCF Ratio | 14.20 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.21, with an EV/FCF ratio of 14.84.
| EV / Earnings | 15.27 |
| EV / Sales | 2.27 |
| EV / EBITDA | 9.21 |
| EV / EBIT | 11.23 |
| EV / FCF | 14.84 |
Financial Position
The company has a current ratio of 4.00, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.00 |
| Quick Ratio | 2.27 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.37 |
| Debt / FCF | 0.60 |
| Interest Coverage | 18.62 |
Financial Efficiency
Return on equity (ROE) is 15.89% and return on invested capital (ROIC) is 17.80%.
| Return on Equity (ROE) | 15.89% |
| Return on Assets (ROA) | 9.77% |
| Return on Invested Capital (ROIC) | 17.80% |
| Return on Capital Employed (ROCE) | 18.32% |
| Weighted Average Cost of Capital (WACC) | 6.73% |
| Revenue Per Employee | 1.59B |
| Profits Per Employee | 236.88M |
| Employee Count | 1,444 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 1.72 |
Taxes
In the past 12 months, Imexpharm has paid 93.88 billion in taxes.
| Income Tax | 93.88B |
| Effective Tax Rate | 20.35% |
Stock Price Statistics
The stock price has decreased by -26.64% in the last 52 weeks. The beta is 0.43, so Imexpharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | -26.64% |
| 50-Day Moving Average | 37,022.00 |
| 200-Day Moving Average | 45,378.75 |
| Relative Strength Index (RSI) | 45.92 |
| Average Volume (20 Days) | 5,540 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Imexpharm had revenue of VND 2.29 trillion and earned 340.63 billion in profits. Earnings per share was 2,105.16.
| Revenue | 2.29T |
| Gross Profit | 1.05T |
| Operating Income | 463.34B |
| Pretax Income | 461.28B |
| Net Income | 340.63B |
| EBITDA | 565.15B |
| EBIT | 463.34B |
| Earnings Per Share (EPS) | 2,105.16 |
Balance Sheet
The company has 522.56 billion in cash and 211.61 billion in debt, with a net cash position of 310.95 billion or 2,019.05 per share.
| Cash & Cash Equivalents | 522.56B |
| Total Debt | 211.61B |
| Net Cash | 310.95B |
| Net Cash Per Share | 2,019.05 |
| Equity (Book Value) | 2.43T |
| Book Value Per Share | 14,036.39 |
| Working Capital | 1.29T |
Cash Flow
In the last 12 months, operating cash flow was 388.39 billion and capital expenditures -37.79 billion, giving a free cash flow of 350.61 billion.
| Operating Cash Flow | 388.39B |
| Capital Expenditures | -37.79B |
| Depreciation & Amortization | 101.81B |
| Net Borrowing | -161.34B |
| Free Cash Flow | 350.61B |
| FCF Per Share | 2,276.54 |
Margins
Gross margin is 46.00%, with operating and profit margins of 20.21% and 16.02%.
| Gross Margin | 46.00% |
| Operating Margin | 20.21% |
| Pretax Margin | 20.12% |
| Profit Margin | 16.02% |
| EBITDA Margin | 24.65% |
| EBIT Margin | 20.21% |
| FCF Margin | 15.29% |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 1.40%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 1.40% |
| Dividend Growth (YoY) | 20.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 25.15% |
| FCF Payout Ratio | 26.36% |
| Buyback Yield | -0.93% |
| Shareholder Yield | 0.47% |
| Earnings Yield | 5.88% |
| FCF Yield | 6.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 17, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Sep 17, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |